Creso Pharma’s subsidiary Halucenex’s key psychedelic ingredient passes crucial testing and is one step closer to phase two clinical trials

In a major step towards a Phase II clinical trial Halucenex has received favourable results from stability testing for its GMP grade psilocybin.

Topic PTSD

Compound Psilocybin

Visit article

Category Press Release

Published in Stockhead

Country Australia

Companies Featured

Creso Pharma
Creso was made to carry drug mastery and methodological meticulousness to the universe of cannabis and convey quality items to individuals and creatures all over.